Natera beats EPS estimate by $0.02, revenue tops forecasts

au.investing.com

Natera Inc reported quarterly earnings that beat analyst estimates by $0.02 per share, while revenue also surpassed expectations. Both metrics outperformed Wall Street projections for the quarter, with earnings per share coming in two cents above consensus. Revenue also exceeded analyst forecasts, indicating robust business activity during the period. Natera specializes in genetic testing and diagnostics. Broader industry trends include increasing use of such tests, while the company still faces competitive and regulatory risks.


With a significance score of 1, this news ranks in the top 65% of today's 33236 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: